Perkins Capital Management Inc. Acquires 236,100 Shares of MDxHealth SA (NASDAQ:MDXH)

Perkins Capital Management Inc. lifted its stake in shares of MDxHealth SA (NASDAQ:MDXH - Free Report) by 31.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 983,475 shares of the company's stock after acquiring an additional 236,100 shares during the quarter. MDxHealth accounts for 2.1% of Perkins Capital Management Inc.'s portfolio, making the stock its 15th largest holding. Perkins Capital Management Inc. owned 2.08% of MDxHealth worth $2,331,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of MDXH. OneDigital Investment Advisors LLC boosted its position in shares of MDxHealth by 15.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company's stock valued at $120,000 after purchasing an additional 7,656 shares during the period. Oppenheimer & Co. Inc. lifted its position in MDxHealth by 100.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock worth $47,000 after buying an additional 10,000 shares in the last quarter. Finally, Maven Securities LTD purchased a new position in shares of MDxHealth during the 3rd quarter valued at $208,000.

MDxHealth Stock Down 0.7 %

Shares of NASDAQ MDXH traded down $0.01 during mid-day trading on Friday, reaching $1.51. The company had a trading volume of 42,930 shares, compared to its average volume of 85,028. The stock has a market capitalization of $71.40 million, a PE ratio of -0.99 and a beta of 1.37. MDxHealth SA has a twelve month low of $1.35 and a twelve month high of $3.50. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The stock's 50 day moving average is $1.75 and its 200-day moving average is $2.00.

Remove Ads

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. The company had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. As a group, equities analysts anticipate that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.